{"product_id":"memorial-sloan-kettering-cancer-center-fundamentals-and-advances-in-immunotherapy-in-the-oncology-patient-2023","title":"Memorial Sloan Kettering Cancer Center Fundamentals and Advances in Immunotherapy in the Oncology Patient 2023","description":"\u003cdiv class=\"prod-title\"\u003e\n\u003ch1 class=\"product_title entry-title\"\u003eMemorial Sloan Kettering Cancer Center Fundamentals and Advances in Immunotherapy in the Oncology Patient 2023\u003c\/h1\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eInclude: 22 videos + 18 pdfs, size: 4.5 GB\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e Target Audience: physicians who care for oncology patients\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSample video: \u003cspan style=\"color: #0000ff\"\u003e\u003ca style=\"color: #0000ff\" href=\"https:\/\/medustudent.com\/contact_us\/\"\u003econtact me\u003c\/a\u003e \u003c\/span\u003efor sample video\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003e Information:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eDate \u0026amp; Location\u003c\/strong\u003e\u003c\/div\u003e\n\u003cp\u003eTuesday, January 24, 2023, 7:50 AM – 5:00 PM, Online, New York , NY\u003c\/p\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eSpecialties\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – Allergy and Immunology, Bone Marrow Transplant, Breast Medical Oncology, Cellular Therapeutics, Critical Care, Gastrointestinal Oncology, Genitourinary Oncology, Gynecologic Oncology, Head and Neck Oncology, Hospice and Palliative Medicine, Immunotherapy, Leukemia, Lymphoma, Medical Oncology, Neurology, Neuro-Oncology, Nurse Practitioner, Nursing, Oncology and Hematology, Pharmacology and Medication Management, Physician Assistant, Pulmonary Medicine, Radiation Oncology, Solid Tumor Oncology\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eOverview\u003c\/strong\u003e\u003c\/div\u003e\n\u003cp\u003eImmunotherapeutics has changed the treatment modalities available to cancer patients in both solid tumors and hematologic malignancies. Since the breakthrough of ipilimumab, there have been fast-paced and ongoing advancements in the field of immunotherapy, revolutionizing clinical management rapidly.\u003c\/p\u003e\n\u003cp\u003eThis one-day live virtual course aims to improve cancer patient outcomes by advancing the science, development, and application of cancer immunology and immunotherapy through fundamental understanding and clinical application. Learners will review fundamental concepts and recent advances in immunotherapy designed to meet the learning needs of advanced practice providers (APPs) and other allied health professionals.\u003c\/p\u003e\n\u003cp\u003eClinical application in solid tumor and hematologic malignancies will be discussed as well as toxicity management, including immune-related adverse events resulting from immune checkpoint inhibition. Experts will discuss the fundamentals of immune checkpoint blockade and CAR T cell therapy, as well as advancements in TIL and BITE therapy, novel combination therapy, and algorithmic management of immune-related adverse events. Toxicity management will be communicated through case study applications and demonstration of common, rare, and severe immune-related adverse events.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWho Should Attend\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe target audience for this course includes nurse practitioners, physician assistants, certified registered nurse anesthetists, physicians, and nurses who care for oncology patients. \u003cstrong\u003eWe are pleased to offer complimentary registration for residents, fellows, APP students, and nursing students.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"activitysectionbold\"\u003eObjectives\u003c\/div\u003e\n\u003col\u003e\n\u003cli\u003eDescribe the principles surrounding the immunity cycle\u003c\/li\u003e\n\u003cli\u003eExplain fundamental principles of immunotherapeutic agents including immune checkpoint inhibition, CAR T CELL , TIL, and BITE therapies.\u003c\/li\u003e\n\u003cli\u003eDiscuss clinical application of immune modulated agents in the oncology population\u003c\/li\u003e\n\u003cli\u003eDiscuss the symptoms of Cytokine release Syndrome and clinical management\u003c\/li\u003e\n\u003cli\u003eRecognize and identify common, rare and severe immune related adverse events attributed to immune checkpoint inhibition\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e Topics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAlgorithmic Management and Grading of Immune-Related Adverse Events.mp4\u003c\/li\u003e\n\u003cli\u003eAlgorithmic Management and Grading of Immune-Related Adverse Events.pdf\u003c\/li\u003e\n\u003cli\u003eAPPImmunotherapy_2023_Brochure.pdf\u003c\/li\u003e\n\u003cli\u003eBITE and CAR T cell therapy in the Acute Leukemia Patient- A Case Study Approach.mp4\u003c\/li\u003e\n\u003cli\u003eBITE and CAR T cell therapy in the Acute Leukemia Patient- A Case Study Approach.pdf\u003c\/li\u003e\n\u003cli\u003eCardiac Immune-Related Adverse Event- Myocarditis.mp4\u003c\/li\u003e\n\u003cli\u003eCardiac Immune-Related Adverse Event- Myocarditis.pdf\u003c\/li\u003e\n\u003cli\u003eClinical Application of Immune Checkpoint Inhibitors in Solid Tumor Malignancy Panel Discussion.mp4\u003c\/li\u003e\n\u003cli\u003eClinical Application of Immune Therapy in Hematologic Malignancy Panel Discussion.mp4\u003c\/li\u003e\n\u003cli\u003eClinical Considerations for Immune Checkpoint Toxicities Panel Discussion.mp4\u003c\/li\u003e\n\u003cli\u003eClinical Updates in Head and Neck Squamous Cell Carcinoma.mp4\u003c\/li\u003e\n\u003cli\u003eClinical Updates in Head and Neck Squamous Cell Carcinoma.pdf\u003c\/li\u003e\n\u003cli\u003eClinical Updates in Lymphoma.mp4\u003c\/li\u003e\n\u003cli\u003eClinical Updates in Lymphoma.pdf\u003c\/li\u003e\n\u003cli\u003eClinical Updates in Metastatic Breast Cancer.mp4\u003c\/li\u003e\n\u003cli\u003eClinical Updates in Metastatic Breast Cancer.pdf\u003c\/li\u003e\n\u003cli\u003eClinical Updates in Myeloma.mp4\u003c\/li\u003e\n\u003cli\u003eClinical Updates in Myeloma.pdf\u003c\/li\u003e\n\u003cli\u003eClinical Updates in Rectal Squamous Cell Carcinoma.mp4\u003c\/li\u003e\n\u003cli\u003eClinical Updates in Rectal Squamous Cell Carcinoma.pdf\u003c\/li\u003e\n\u003cli\u003eClinical Updates in Sarcoma and Merkel Cell Carcinoma.mp4\u003c\/li\u003e\n\u003cli\u003eClinical Updates in Sarcoma and Merkel Cell Carcinoma.pdf\u003c\/li\u003e\n\u003cli\u003eClnical Updates in Non-Small Cell Lung Cancer.mp4\u003c\/li\u003e\n\u003cli\u003eClnical Updates in Non-Small Cell Lung Cancer.pdf\u003c\/li\u003e\n\u003cli\u003eCytokine Release Syndrome.mp4\u003c\/li\u003e\n\u003cli\u003eCytokine Release Syndrome.pdf\u003c\/li\u003e\n\u003cli\u003eDiscussion of Novel Checkpoint Inhibitors and Combination Therapy.mp4\u003c\/li\u003e\n\u003cli\u003eDiscussion of Novel Checkpoint Inhibitors and Combination Therapy.pdf\u003c\/li\u003e\n\u003cli\u003eFundamentals of Immune Checkpoint Blockade Panel Discussion.mp4\u003c\/li\u003e\n\u003cli\u003eFundamentals of T Cell Therapy Panel Discussion.mp4\u003c\/li\u003e\n\u003cli\u003eGastrointestinal Immune-Related Adverse Event- Colitis.mp4\u003c\/li\u003e\n\u003cli\u003eGastrointestinal Immune-Related Adverse Event- Colitis.pdf\u003c\/li\u003e\n\u003cli\u003eMechanism of Action and Clinical Applications of Tumor Infiltrating Lymphocytic (TIL) Therapy.mp4\u003c\/li\u003e\n\u003cli\u003eMechanism of Action and Clinical Applications of Tumor Infiltrating Lymphocytic (TIL) Therapy.pdf\u003c\/li\u003e\n\u003cli\u003eMechanism of Action of Checkpoint Blockade PD1, PDL1, CTLA-4.mp4\u003c\/li\u003e\n\u003cli\u003eMechanism of Action of Checkpoint Blockade PD1, PDL1, CTLA-4.pdf\u003c\/li\u003e\n\u003cli\u003eNeurological Immune-Related Adverse Event- Myasthenia Gravis.mp4\u003c\/li\u003e\n\u003cli\u003eNeurological Immune-Related Adverse Event- Myasthenia Gravis.pdf\u003c\/li\u003e\n\u003cli\u003eOverview of Chimeric Antigen Receptor (CAR) T Cell Immunotherapy.mp4\u003c\/li\u003e\n\u003cli\u003eOverview of Chimeric Antigen Receptor (CAR) T Cell Immunotherapy.pdf\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n","brand":"My Store","offers":[{"title":"Default Title","offer_id":42954627842146,"sku":"MED-AMB07098","price":30.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Memorial-Sloan-Kettering-Cancer-Center-Fundamentals-and-Advances-in-Immunotherapy-in-the-Oncology-Patient-2023.jpg?v=1779381132","url":"https:\/\/meducourse.com\/products\/memorial-sloan-kettering-cancer-center-fundamentals-and-advances-in-immunotherapy-in-the-oncology-patient-2023","provider":"Meducourse","version":"1.0","type":"link"}